Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study
Journal of Clinical Medicine · 24.12.2024 · 14 (1) · 6
DOI: 10.3390/jcm14010006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.12.2024. Verfasst von Anita Gąsiorowska und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Medical University of Lodz, Pomorska 251, 92-213 Łódź, Poland. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DSM-Firmenich (Kaiseraugst, Switzerland).
Abstract (Originalsprache)
Objective
Biotics are increasingly being used in the treatment of irritable bowel syndrome (IBS). This study aimed to assess the efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics (Lactocaseibacillus rhamnosus DSM 26357, Lactobacillus acidophilus DSM 32418, Bifidobacterium longum DSM 32946, Bifidobacterium bifidum DSM 32403, and Bifidobacterium lactis DSM 32269), and short-chain fructooligosaccharides (scFOSs) in IBS patients.
Methods
This was a randomized, double-blind, placebo-controlled trial involving 120 adult participants with IBS. The primary outcome of the 12-week intervention was the improvement in IBS symptoms and quality of life (QOL), assessed with the use of IBS-Adequate Relief (IBS-AR), IBS-Global Improvement Scale (IBS-GIS), IBS-Symptom Severity Score (IBS-SSS), and IBS-QOL. Secondary outcomes were the number and type of stools (assessed via the Bristol Stool Form scale), patient-recorded symptoms, anthropometric parameters, and levels of selected inflammatory cytokines.
Results
As early as at 4 weeks, there was a higher percentage of patients in the biotic group reporting adequate relief of symptoms (based on IBS-AR) than in the placebo group (64.7% vs. 42.0%, respectively, p = 0.023). At 12 weeks, fewer patients in the biotic group reported a ‘worsening of symptoms’ (based on IBS-GIS) than in the placebo group (5.9% vs. 16.0% respectively, p = 0.015). There were no significant differences between groups in IBS-QOL or IBS-SSS or any of the secondary outcome measures except the patient-recorded ‘urgency to defecate’ (p = 0.015) at week 12, which was significantly lower in the biotic group. The intervention was safe and well tolerated.
Conclusions
A biotic mixture consisting of microencapsulated butyrate, probiotics, and small amounts of scFOSs is safe and effective in improving gastrointestinal symptoms in patients with IBS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology Department, Medical University of Lodz, Pomorska 251, 92-213 Łódź, Poland.
- Department of Microbiology and Clinical Immunology, The Children's Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.
- Health, Nutrition & Care, DSM-Firmenich, 4303 Kaiseraugst, Switzerland.
- Department of Pathomorphology, The Children's Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.
- Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zürich, 8091 Zürich, Switzerland.
ORCID-Profile: Anita Gąsiorowska, Cezary Chojnacki, Joanna B Bierła, Bożena Cukrowska
Förderung
- DSM-Firmenich (Kaiseraugst, Switzerland)
Zitieren
APA
Gąsiorowska, A., Romanowski, M., Walecka-Kapica, E., Kaczka, A., Chojnacki, C., Padysz, M., Siedlecka, M., Banasik, J., Sobolewska-Włodarczyk, A., Wiśniewska-Jarosińska, M., Bierła, J. B., Otaru, N., Cukrowska, B., & Steinert, R. E. (2024). Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Medicine, 14(1), 6. https://doi.org/10.3390/jcm14010006
Vancouver
Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, Padysz M, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Medicine. 2024;14(1):6. doi:10.3390/jcm14010006
BibTeX
@article{Gsiorowska2024,
author = {Gąsiorowska, Anita and Romanowski, Marek and Walecka-Kapica, Ewa and Kaczka, Aleksandra and Chojnacki, Cezary and Padysz, Milena and Siedlecka, Marta and Banasik, Julia and Sobolewska-Włodarczyk, Aleksandra and Wiśniewska-Jarosińska, Maria and Bierła, Joanna B and Otaru, Nize and Cukrowska, Bożena and Steinert, Robert E},
title = {Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {14},
number = {1},
pages = {6},
doi = {10.3390/jcm14010006}
}
EUVIMED